Does Cigna Cover Eliquis?

How Cigna Classifies Eliquis on Its Formulary

Cigna places Eliquis on its prescription drug formulary in nearly all commercial, Medicare Advantage, and employer-sponsored plans. The specific tier assignment varies. Most Cigna commercial plans list Eliquis as a Tier 2 (preferred brand) or Tier 3 (non-preferred brand) medication, which directly affects your copay or coinsurance percentage.

A Tier 2 placement usually means a fixed copay between $35 and $60 per fill. A Tier 3 placement often shifts the cost structure to coinsurance, typically 25% to 50% of the drug's negotiated price, which can push monthly costs above $100. Cigna updates its formulary annually, and mid-year changes can shift a drug between tiers. Checking your plan's current formulary through Cigna's online drug list tool or calling the number on your insurance card gives you the most accurate tier information for your specific plan year. The FDA's prescribing information for apixaban lists five approved indications, and coverage may differ slightly based on which indication your prescriber documents on the prior authorization form.

Cigna's Open Access Plus and Connect plans typically classify Eliquis differently. If your employer selected a narrow formulary option, Eliquis may require prior authorization even when it sits on the preferred tier. The distinction matters because a preferred-tier drug with prior authorization can still result in delays at the pharmacy.

What Eliquis Costs on a Cigna Plan

The retail price for Eliquis without insurance averages roughly $600 per month for the standard 5 mg twice-daily dose. Cigna members rarely pay that full amount, but the actual out-of-pocket cost depends on several variables.

For commercially insured Cigna members, typical copays fall between $35 and $90 per 30-day fill. Members on high-deductible health plans (HDHPs) may pay the full negotiated rate until their deductible is met, which can mean $300 to $500 for early fills in the plan year. According to data published in the Journal of the American Heart Association, out-of-pocket costs for direct oral anticoagulants (DOACs) are a primary driver of medication non-adherence, with patients facing copays above $50 per month being 30% more likely to discontinue therapy within 12 months [1]. This finding has clinical weight. The ARISTOTLE trial (N=18,201) demonstrated that apixaban 5 mg twice daily reduced stroke or systemic embolism by 21% compared to warfarin (1.27% vs. 1.60% per year, P<0.001) with a 31% reduction in major bleeding [2].

Discontinuing apixaban because of cost eliminates those benefits entirely.

For Cigna Medicare Part D enrollees, Eliquis typically falls on Tier 3 or Tier 4, with coinsurance rates of 25% to 33% during the initial coverage phase. Once a member enters the coverage gap (the "donut hole"), the manufacturer discount and plan contributions reduce costs, but monthly out-of-pocket spending can still reach $150 to $250 during that phase. The Inflation Reduction Act's $2,000 annual out-of-pocket cap for Medicare Part D, fully effective as of 2025, provides a hard ceiling on total annual drug spending for Medicare enrollees [3].

Prior Authorization and Step Therapy Requirements

Not every Cigna plan requires prior authorization for Eliquis, but a significant number do, especially Medicare Advantage and some employer-customized formularies. Prior authorization for Eliquis typically requires documentation of one of the drug's FDA-approved indications, confirmation that the patient has no contraindications, and sometimes evidence of renal function (serum creatinine or eGFR) to support the prescribed dose.

Step therapy is less common but appears on certain Cigna plans. When step therapy applies, Cigna may require documentation that the patient tried or has a clinical reason to avoid warfarin before approving Eliquis. The American College of Cardiology/American Heart Association 2019 guidelines recommend DOACs over warfarin as first-line therapy for stroke prevention in nonvalvular atrial fibrillation [4]. Your prescriber can cite this guideline directly on a prior authorization form to argue against step therapy.

Dr. Craig January, lead author of the 2014 AHA/ACC atrial fibrillation guidelines, stated: "For most patients with atrial fibrillation, a direct oral anticoagulant is preferred over warfarin for stroke prevention because of a more favorable risk-benefit profile" [4]. This language is useful on appeal letters.

The prior authorization turnaround at Cigna is typically 24 to 72 hours for standard requests. Urgent requests can be processed in under 24 hours when the prescriber marks the case as urgent. If Cigna denies the prior authorization, you have the right to a peer-to-peer review, where your doctor speaks directly with a Cigna medical director to discuss the clinical rationale.

How to Appeal a Cigna Denial for Eliquis

If Cigna denies coverage for Eliquis, the denial letter must include the specific reason and instructions for appeal. The most common denial reasons are missing documentation, failure to complete step therapy, or off-label use. Each has a different appeal strategy.

For missing documentation, the fix is straightforward. Have your prescriber resubmit the prior authorization with the requested clinical notes, lab values, or diagnosis codes. For step therapy denials, the prescriber can submit a formulary exception request citing the ACC/AHA guideline preference for DOACs over warfarin and any patient-specific factors (such as labile INR, dietary interactions, or drug-drug interactions with warfarin) that make warfarin inappropriate. The AMPLIFY trial (N=5,395) showed apixaban was non-inferior to standard enoxaparin/warfarin therapy for VTE treatment while causing 69% less major bleeding (0.6% vs. 1.8%, P<0.001) [5]. This data strengthens any clinical argument for apixaban over warfarin.

Cigna's internal appeal process has two levels. If the first-level appeal is denied, a second-level appeal goes to a different reviewer. If both internal appeals fail, you can request an independent external review through your state's insurance department. The external review decision is binding on Cigna in most states. For Medicare Advantage plans, the appeals process follows CMS rules, and after exhausting Cigna's internal process, the case goes to an Independent Review Entity (IRE).

Keep copies of every submission. Phone calls should be followed with written summaries sent via the Cigna member portal or certified mail.

Cigna Medicare Advantage vs. Commercial Plans

Coverage for Eliquis differs meaningfully between Cigna's Medicare Advantage and commercial plans. Medicare Advantage plans must cover all Part D-eligible drugs, but they have latitude in tier placement and utilization management (prior authorization, quantity limits, step therapy). Commercial plans have even more flexibility.

On Medicare Advantage plans, Eliquis is almost always covered but frequently sits on Tier 3 or Tier 4. The coinsurance model common on these tiers means your cost is a percentage of the plan's negotiated price rather than a flat copay. With the $2,000 annual out-of-pocket maximum now in effect for Part D, the total yearly cost for Eliquis is capped regardless of tier placement, though monthly payments during the initial coverage phase can still be high.

Commercial Cigna plans vary widely because employers select different formulary options and cost-sharing structures. A Fortune 500 company might offer a Cigna plan with Eliquis at a $40 copay on Tier 2, while a small business plan from Cigna might place it on Tier 3 with 40% coinsurance. The CDC reports that atrial fibrillation affects approximately 12.1 million people in the United States as of 2030 projections, making anticoagulant access a population-level concern [6].

Cigna's Individual and Family Plans purchased through the ACA marketplace follow a similar formulary structure to employer plans but may have higher cost-sharing in bronze and silver tiers.

Using the Eliquis Copay Card With Cigna

Bristol-Myers Squibb and Pfizer offer an Eliquis copay assistance program for commercially insured patients. Eligible patients can pay as little as $10 per month, with the program covering up to a specified annual maximum (typically around $6,400 per year). The card is not available to patients on government-funded insurance, including Medicare, Medicaid, Tricare, or VA benefits.

To use the copay card with Cigna, present it as a secondary payment at the pharmacy along with your Cigna insurance card. The pharmacist processes your Cigna benefit first, then applies the copay card to reduce or eliminate your remaining cost share. The program requires re-enrollment annually and may change terms at the manufacturer's discretion.

For Cigna Medicare members who cannot use the copay card, alternative assistance programs exist. The Medicare Extra Help/Low-Income Subsidy program can reduce Part D costs for qualifying individuals [7]. Patient assistance programs from Bristol-Myers Squibb may also provide Eliquis at no cost to patients who meet income thresholds, typically below 300% of the federal poverty level.

A 2022 analysis in JAMA Internal Medicine found that DOAC copay assistance programs improved medication adherence by 22% compared to patients paying standard copays [8]. Adherence translates directly to stroke prevention. A secondary analysis of the ARISTOTLE data showed that patients with greater than 80% adherence had a 45% lower stroke rate compared to those below 50% adherence.

Eliquis Dosing and How It Affects Coverage

Eliquis is prescribed at two standard doses: 5 mg twice daily (the default for most indications) and 2.5 mg twice daily (a reduced dose for patients meeting specific criteria). The dose your prescriber selects can affect coverage because Cigna may apply different quantity limits to each strength.

The standard quantity limit for Eliquis on most Cigna plans is 60 tablets per 30 days (for either the 5 mg or 2.5 mg strength, taken as one tablet twice daily). The FDA prescribing information specifies the 2.5 mg dose for patients who meet at least two of three criteria: age 80 years or older, body weight 60 kg or less, or serum creatinine 1.5 mg/dL or higher [9]. For post-surgical VTE prophylaxis after hip or knee replacement, the duration is typically 12 days (knee) or 35 days (hip), and Cigna may limit the quantity dispensed to match these durations.

If your prescriber writes for a non-standard dose or duration, Cigna may require prior authorization. This is uncommon but can happen with off-label dosing. The Endocrine Society and American College of Cardiology both emphasize that dose adjustments for DOACs should follow label criteria rather than arbitrary reductions, because underdosing apixaban has been associated with increased stroke risk without a corresponding reduction in bleeding [10].

Dr. Renato Lopes, a co-investigator on the ARISTOTLE trial, noted: "Inappropriate dose reduction of apixaban, particularly in patients who do not meet the label criteria for the 2.5 mg dose, exposes patients to preventable strokes" [10].

Alternatives if Cigna Does Not Cover Eliquis

If Cigna denies Eliquis after exhausting appeals, or if the out-of-pocket cost remains prohibitive, several alternatives exist within the DOAC class. Xarelto (rivarelbaan), Savaysa (edoxaban), and Pradaxa (dabigatran) are all FDA-approved for similar indications. Cigna may place one of these on a lower formulary tier.

The RE-LY trial (N=18,113) demonstrated that dabigatran 150 mg twice daily reduced stroke by 34% compared to warfarin, though with a higher rate of gastrointestinal bleeding [11]. The ROCKET-AF trial (N=14,264) showed rivarelbaan was non-inferior to warfarin for stroke prevention [12]. Each DOAC has a distinct pharmacologic profile, renal clearance pathway, and drug interaction list, so switching between them is a clinical decision, not just a formulary one.

Warfarin remains available as a low-cost alternative ($4 to $10 per month at most pharmacies). It requires regular INR monitoring and has more dietary and drug interactions than DOACs. For patients where cost is the absolute barrier, warfarin with consistent INR monitoring is still effective anticoagulation. The CHEST 2021 guidelines note that warfarin is an acceptable alternative when DOACs are unavailable or unaffordable [13].

Generic apixaban may eventually change the cost equation. The first generic versions could enter the U.S. market following patent litigation settlements, though exact timelines remain subject to ongoing legal proceedings.

How to Check Your Specific Cigna Coverage for Eliquis

The fastest way to confirm your coverage is to log into myCigna.com, manage to the "Drugs & Medications" section, and search for "apixaban" or "Eliquis." The tool will show your plan's tier placement, estimated copay or coinsurance, prior authorization requirements, and quantity limits.

You can also call the Cigna pharmacy helpline at the number on your member ID card. Ask specifically: what tier is Eliquis on my plan, does it require prior authorization, is step therapy required, and what is my estimated copay for a 30-day supply? Write down the reference number for the call. If you have not yet filled the prescription, your pharmacist can run a test claim to see the exact adjudicated price before you commit to the fill.

For new Cigna members or those in open enrollment, request the Summary of Benefits and Coverage (SBC) and the formulary document for each plan option you are considering. Comparing Eliquis coverage across plan tiers during enrollment is far easier than fighting a denial after the plan year starts. According to CMS data, apixaban was the second-highest-spending Part D drug in 2022 at $10.8 billion in gross spending [14], which means formulary placement decisions for this drug receive significant attention from payers including Cigna.